Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.
CONCLUSIONS: In cancer patients with anthracycline therapy, prophylactic β blockers were associated with reduced risk of heart failure, decreased left ventricular diameter, improved left ventricular systolic function, and alleviative cardiomyocyte injury.
PMID: 31023386 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Beta-Blockers | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Failure | Toxicology